Evergreen Capital Management LLC Purchases 48,179 Shares of Merck & Co., Inc. $MRK

by · The Cerbat Gem

Evergreen Capital Management LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 43.3% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 159,559 shares of the company’s stock after purchasing an additional 48,179 shares during the period. Evergreen Capital Management LLC’s holdings in Merck & Co., Inc. were worth $14,450,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in MRK. Barnes Dennig Private Wealth Management LLC acquired a new position in Merck & Co., Inc. during the 1st quarter valued at about $27,000. MorganRosel Wealth Management LLC bought a new position in shares of Merck & Co., Inc. in the first quarter valued at approximately $36,000. Spurstone Advisory Services LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $37,000. Minot DeBlois Advisors LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $45,000. Finally, Mpwm Advisory Solutions LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 1.0%

Shares of NYSE:MRK opened at $83.24 on Friday. The stock’s 50-day moving average price is $82.04 and its 200-day moving average price is $83.02. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $120.30. The stock has a market capitalization of $207.90 billion, a P/E ratio of 12.83, a price-to-earnings-growth ratio of 0.89 and a beta of 0.38. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The firm had revenue of $15.81 billion for the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 49.92%.

Wall Street Analysts Forecast Growth

MRK has been the topic of several recent research reports. Citigroup restated a “neutral” rating and set a $84.00 target price (down previously from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. Wells Fargo & Company cut their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Cantor Fitzgerald lowered Merck & Co., Inc. from an “overweight” rating to a “cautious” rating in a report on Tuesday, May 20th. Finally, Morgan Stanley lowered their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Hold” and an average target price of $107.44.

Get Our Latest Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).